Ticker LaunchIPO · CINC
CinCor Pharma, Inc.
CinCor Pharma, Inc. (CINC) priced its initial public offering on Jan 7, 2022 at $16.00 per share, within its $15.00–$17.00 range, raising $193.6M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $584.3M. Cooley advised the company and WilmerHale advised the underwriters.
CinCor Pharma, Inc. is a drug developer focused on aldosterone-related diseases. Its candidate CIN-107 is designed to selectively inhibit aldosterone synthase without affecting cortisol synthesis, addressing the lack of selectivity that has hampered other programs.
- Status
- IPO
- Ticker
- CINC
- Exchange
- Nasdaq Global Market
- Priced
- Jan 7, 2022
- IPO price
- $16.00
- Price range
- $15.00–$17.00
- Raised
- $193.6M
- Market cap at IPO price
- $584.3M
- First filed
- Dec 17, 2021
- Company counsel
- Cooley
- Underwriters' counsel
- WilmerHale
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Dec 17, 2021
- Latest amendment Jan 3, 2022
- Final prospectus (424B4) Jan 7, 2022
- All filings on EDGAR CIK 1868734
Other Biotech & pharma IPOs in 2022
- Smart for Life, Inc.SMFL · Feb 17, 2022 · $14.4M
- TC BioPharm (Holdings) plcTCBP · Feb 14, 2022
- Nuvectis Pharma, Inc.NVCT · Feb 7, 2022
- Arcellx, Inc.ACLX · Feb 7, 2022 · $123.8M
- Amylyx Pharmaceuticals, Inc.AMLX · Jan 10, 2022 · $190M
- Vigil Neuroscience, Inc.VIGL · Jan 10, 2022 · $98M